2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Pathology, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Checkpoint Inhibitor, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, LGL, Non-Hodgkin Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult
PAPER

5352 First-line pembrolizumab plus radiotherapy in patients with early-stage natural killer/T-cell lymphoma (IELSG50): A single-arm, multicenter, phase 2 trial

Huijuan Zhong, Chun-Yan Chen2, Jie Xiong, PhD3, Gang Cai4, Peng SUN, PhD5, Panpan LIU6, Pengpeng Xu, MD7, Ming-Ci Cai8, Hang Yang9, Yu Wang10, Ying Huang11, Hong-Mei Yi12, Lei Dong13, Hao Zhang14, Qi Song15, Xu-Feng Jiang16, Hao-Xu Yang17, Jia-Yi Zhao18, Rong-Ji Mu19, Jia-Yi Chen20, Wang Li, MD21, Stefano Luminari Sr, MD22, Emanuele Zucca, MD23, Franco Cavalli24, Shu Cheng, MD25, Zhiming Li, MD26, Wei Li Zhao III, Certified Doctor27
1 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
3 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
4 Department of Radiation Oncology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
5 Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
6 Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
7 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
8 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
9 Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
10 Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
11 Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
12 Department of Pathology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
13 Department of Pathology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
14 Department of Otolaryngology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
15 Department of Radiology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
16 Department of Nuclear Medicine, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,, Shanghai, China
17 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
18 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
19 Shanghai Jiao Tong University School of Medicine, Shanghai, China
20 Department of Radiation Oncology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
21 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
22 Division of Hematology, Azienda Unità Sanitaria Locale-IRCCS, Reggio Emilia, Italy
23 Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland, Institute of Oncology Research, Bellinzona, Switzerland, Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland
24 Foundation for the Institute of Oncology Research, Bellinzona, Switzerland
25 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
26 Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
27 Pôle de Recherches Sino-Français en Science du Vivant et Génomique, Laboratory of Molecular Pathology, Shanghai, China, Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

Background Natural killer/T-cell lymphoma (NKTCL) is highly aggressive, characterized by Epstein-Barr virus infection and overexpressed immune checkpoints. This study aims to evaluate the efficacy and safety of pembrolizumab plus radiotherapy in patients with newly diagnosed early-stage NKTCL.

Methods This is a single-arm, multicenter, phase 2 trial. Eligible patients met the following criteria: (1) age ≥ 18 years; (2) newly diagnosed NKTCL with Ann Arbor stage I-II disease; (3) presence of at least one risk factor (age > 60 years, elevated serum lactate dehydrogenase, Ann Arbor stage II or primary tumor invasion); (4) ineligible for systemic chemotherapy. All patients received induction therapy with 6 cycles of pembrolizumab (200mg intravenously on day 1 every 21 days) plus concurrent radiotherapy. Patients with complete remission (CR), partial remission, or stable disease proceeded to pembrolizumab maintenance (200mg every 21 days, up to 35 cycles). The primary endpoint was 2-year progression-free survival (PFS) rate. The main secondary endpoints included CR rate (CRR), overall response rate (ORR), 2-year overall survival (OS) rate and adverse events.

Results From August 2022 to January 2025, a total of 30 patients with a median age of 62 years (IQR, 45-69) were enrolled, and 17 (56.7%) patients were aged > 60 years. All patients were intermediate (60%, n=18) and high (40%, n=12) risk according to the nomogram-revised risk index. Until April 30, 2026, the median follow-up time was 25.4 months (95%CI 23.7-27.2), the 2-year PFS rate was 68.0% (95%CI 52.3-88.3), and the 2-year OS rate was 74.9% (95%CI 60.2-93.2), respectively. The best CRR and best ORR were 83.3% (95%CI, 65.3-94.4) and 90.0% (95%CI, 73.5-97.9), respectively. The treatment was well-tolerated. The most common grade 3-4 adverse events included lymphocytopenia, oral mucositis, and leukopenia. 80.0% of patients with detectable baseline plasma EBV DNA attained EBV clearance after induction therapy. Biomarker analyses indicated that patients with PD-L1 CPS ≥ 25 and/or 9p24.1 copy gain (19 of 24 patients with available data) achieved superior survival.

Conclusions Pembrolizumab combined with concurrent radiotherapy demonstrated encouraging efficacy and safety profile as first-line therapy for early-stage NKTCL with adverse risk features. Patients with PD-L1 upregulation significantly benefited from this regimen.

Huijuan Zhong: No relevant conflicts of interest to declare.